Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levofloxacin-based versus clarithromycin-based triple therapy for Helicobacter pylori eradication
IRCT20210209050313N1Phase 3Completed
- Sponsor
- Tehran University of Medical Sciences
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of levofloxacin and clarithromycin in Helicobacter pylori infection (2 arms), sponsored by Tehran University of Medical Sciences. Primary endpoints: Helicobacter pylori eradication rate, Adherence rate and 1 more. Started Jul 2021; status: completed.
02
Drugs
levofloxacinclarithromycin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20210209050313N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210209050313N1.